» Articles » PMID: 35557505

Alzheimer's Disease Assessments Optimized for Diagnostic Accuracy and Administration Time

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Despite the potential of machine learning techniques to improve dementia diagnostic processes, research outcomes are often not readily translated to or adopted in clinical practice. Importantly, the time taken to administer diagnostic assessment has yet to be taken into account in feature-selection based optimisation for dementia diagnosis. We address these issues by considering the impact of assessment time as a practical constraint for feature selection of cognitive and functional assessments in Alzheimer's disease diagnosis.

Methods: We use three different feature selection algorithms to select informative subsets of dementia assessment items from a large open-source dementia dataset. We use cost-sensitive feature selection to optimise our feature selection results for assessment time as well as diagnostic accuracy. To encourage clinical adoption and further evaluation of our proposed accuracy-vs-cost optimisation algorithms, we also implement a sandbox-like toolbox with graphical user interface to evaluate user-chosen subsets of assessment items.

Results: We find that there are subsets of accuracy-cost optimised assessment items that can perform better in terms of diagnostic accuracy and/or total assessment time than most other standard assessments.

Discussion: Overall, our analysis and accompanying sandbox tool can facilitate clinical users and other stakeholders to apply their own domain knowledge to analyse and decide which dementia diagnostic assessment items are useful, and aid the redesigning of dementia diagnostic assessments. Clinical Impact (Clinical Research): By optimising diagnostic accuracy and assessment time, we redesign predictive and efficient dementia diagnostic assessments and develop a sandbox interface to facilitate evaluation and testing by clinicians and non-specialists.

Citing Articles

RECOVER-NEURO: study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC).

Knopman D, Laskowitz D, Koltai D, Charvet L, Becker J, Federman A Trials. 2024; 25(1):326.

PMID: 38755688 PMC: 11098733. DOI: 10.1186/s13063-024-08156-z.


Are Advanced Clinical Practitioners perfectly placed to re-report neuroimages to support clinical diagnosis of dementia?.

Bradley D, Harrison J, Goodall M, Dobrashian R Int J Adv Pract. 2024; 1(3):146-150.

PMID: 38229770 PMC: 7615529. DOI: 10.12968/ijap.2023.1.3.146.


Hierarchical Two-Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer's Disease and Related Dementias.

Kleiman M, Ariko T, Galvin J J Alzheimers Dis. 2022; 91(2):895-909.

PMID: 36502329 PMC: 10515190. DOI: 10.3233/JAD-220891.

References
1.
Goldberg T, Harvey P, Wesnes K, Snyder P, Schneider L . Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimers Dement (Amst). 2016; 1(1):103-11. PMC: 4876902. DOI: 10.1016/j.dadm.2014.11.003. View

2.
McCombe N, Liu S, Ding X, Prasad G, Bucholc M, Finn D . Practical Strategies for Extreme Missing Data Imputation in Dementia Diagnosis. IEEE J Biomed Health Inform. 2021; 26(2):818-827. DOI: 10.1109/JBHI.2021.3098511. View

3.
Bourque M, Foley T . Improving the Quality of Dementia Care in General Practice: A Qualitative Study. Front Med (Lausanne). 2020; 7:600586. PMC: 7724029. DOI: 10.3389/fmed.2020.600586. View

4.
Ding X, Bucholc M, Wang H, Glass D, Wang H, Clarke D . A hybrid computational approach for efficient Alzheimer's disease classification based on heterogeneous data. Sci Rep. 2018; 8(1):9774. PMC: 6021389. DOI: 10.1038/s41598-018-27997-8. View

5.
El-Hayek Y, Wiley R, Khoury C, Daya R, Ballard C, Evans A . Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. J Alzheimers Dis. 2019; 70(2):323-341. PMC: 6700654. DOI: 10.3233/JAD-190426. View